An 8-Week Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Oral Fispemifene for the Treatment of Sexual Dysfunction in Hypogonadal Men

Trial Profile

An 8-Week Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Oral Fispemifene for the Treatment of Sexual Dysfunction in Hypogonadal Men

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 28 Mar 2016

At a glance

  • Drugs Fispemifene (Primary)
  • Indications Hypogonadism; Lower urinary tract symptoms; Prostatitis
  • Focus Proof of concept; Therapeutic Use
  • Sponsors NexMed (USA)
  • Most Recent Events

    • 28 Mar 2016 Primary endpoint has not been met, (Change in IIEF-EF (International Index of Erectile Function - erectile function domain) score), according to Apricus Biosciences media release.
    • 28 Mar 2016 Top-line results of this trial published in an Apricus Biosciences media release.
    • 06 Jan 2016 According to Apricus media release, company is planning to report top-line data of this trial in the first quarter of 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top